Preoperative metronidazole treatment to evaluate its efficacy in reducing Fusobacterium nucleatum colonisation in colorectal cancer patients: a proof-of-concept trial
Forty patients newly diagnosed with CRC, for whom surgical resection is planned, will receive metronidazole for 10 days before surgery, which must be scheduled within 3 days following the last administration. Patients who do not receive the treatment for at least 7 days will be deemed ineligible for the study and will be replaced. <i>Fusobacterium nucleatum</i> abundance will be assessed through specific quantitative PCR analysis on genomic DNA extracted from diagnostic biopsies and excised tissues, with comparative analysis.
Authors
- Milo Frattini
- Gianluca Lollo
- F. Radaelli
- Giandomenica Iezzi (ORCID: https://orcid.org/0000-0001-5841-495X)
- Alberto Vannelli (ORCID: https://orcid.org/0000-0002-8894-5361)
- Paolo Gaffuri (ORCID: https://orcid.org/0000-0002-6681-6876)
- Dimitrios Christoforidis (ORCID: https://orcid.org/0000-0002-8194-282X)
- Sotirios Georgios Popeskou (ORCID: https://orcid.org/0000-0001-8971-5624)
- Sara De Dosso (ORCID: https://orcid.org/0000-0001-6424-6307)
- Ken Galetti (ORCID: https://orcid.org/0000-0002-9037-991X)
- Elisabetta Merlo
- Luciana Ambrosiani
- Mario Marengo (ORCID: https://orcid.org/0000-0001-7365-3553)
Institutions
- Ospedale regionale di Lugano (CH)
- Ente Ospedaliero Cantonale (CH)
- Institute of Oncology Research (CH)
- Ospedale Regionale di Locarno (CH)
- Ospedale Regionale di Mendrisio (CH)
- Ospedale Regionale di Bellinzona e Valli (CH)
- Istituto Cantonale di Patologia (CH)
- Ospedale Valduce (IT)
- Università della Svizzera italiana (CH)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100169
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00